GLB-001
/ GluBio Therap
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 04, 2024
GLB-001-02: A Study of GLB-001 in Patients With Myeloid Malignancies
(clinicaltrials.gov)
- P1 | N=108 | Recruiting | Sponsor: Hangzhou GluBio Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Acute Myelogenous Leukemia • Essential Thrombocythemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera • Thrombocytosis • JAK2
April 22, 2024
A Study of GLB-001 in Patients With Myeloid Malignancies
(clinicaltrials.gov)
- P1 | N=108 | Not yet recruiting | Sponsor: Hangzhou GluBio Pharmaceutical Co., Ltd.
New P1 trial • Acute Myelogenous Leukemia • Essential Thrombocythemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera • Thrombocytosis • JAK2
November 27, 2023
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: GluBio Therapeutics Inc.
New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
1 to 3
Of
3
Go to page
1